Glenmark Pharmaceuticals has released Latanoprost Ophthalmic Solution, 0.005 percent (0.05 mg/mL).

Glenmark’s Latanoprost Ophthalmic Solution, 0.005 percent (0.05 mg/mL) is bioequivalent and therapeutically equivalent to the reference listed drug, Xalatan®2 Ophthalmic Solution, 0.005 percent of Upjohn US.

According to IQVIATM sales data for the 12-month period ending December 2024, the Xalatan® Ophthalmic Solution, 0.005 percent market3 achieved annual sales of approximately USD 113.5 million.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, “We are excited to announce the launch of our 4th ophthalmic product, Latanoprost Ophthalmic Solution, 0.005 percent (0.05 mg/mL), growing our portfolio of products within the ophthalmic channel. This addition highlights our commitment to meeting market needs and providing quality solutions for our customers.”

Glenmark Pharmaceuticals Ltd. is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries.

Glenmark’s Green House Gas (GHG) emission reduction targets have been approved in 2023 by the Science Based Target initiative (SBTi), making it only the second pharmaceutical company in India to achieve this.